Latest in Pulmonary News

Latest in Pulmonary News2019-02-15T07:28:32-05:00

Thirty-Day Hospital Readmission Metric Linked to Increased Mortality for HF and Pneumonia

Physicians are at increased pressure to reduce readmissions for certain chronic diseases. A recent study found that implementation of the 30-day readmission rules has been associated with increased 30-day post-discharge mortality for those hospitalized for heart failure and pneumonia.

Post-discharge deaths have increased by 0.25% for patients hospitalized with heart failure and by 0.40% for patients with pneumonia since the implementation of the 30-day readmission rules.
There are approximately 8 million hospitalizations during the study period. Such small increases may account for a large number of deaths.

The findings, published online in JAMA, come from a retrospective cohort study that compared mortality rates among 8.3 million Medicare beneficiaries hospitalized for these common conditions before and after implementation of the Hospital Readmissions Reduction Program (HRRP). This early data should lead physicians to exercise caution in discharging patients prematurely.

Source: Association of the Hospital Readmissions Reduction Program With Mortality Among Medicare Beneficiaries Hospitalized for Heart Failure, Acute Myocardial Infarction, and Pneumonia. JAMA. 2018;320(24):2542-2552. doi:10.1001/jama.2018.19232

Add Corticosteroids to Your Arsenal for the treatment of Inpatient Community-Acquired Pneumonia.

Corticosteroids were both beneficial and cost-effective for hospitalized adults with severe CAP. Hospitalized people with non-severe CAP may also benefit from corticosteroid therapy, but with no survival advantage

In 2015, results of two randomized trials showed that systemic corticosteroids were beneficial for some hospitalized patients with community-acquired pneumonia (CAP; NEJM JW Gen Med Mar 15 2015 and JAMA 2015; 313:677; NEJM JW Gen Med Mar 1 2015 and Lancet 2015; 385:1511). Now, two new meta-analyses — one by the Cochrane Library, and one by the Infectious Diseases Society of America (IDSA) — address whether CAP patients should receive systemic corticosteroids routinely.

These meta-analyses suggest that low-dose (≈40 mg), short-course (3–7 days) systemic corticosteroids should be strongly considered for hospitalized adults with severe CAP. These results do not apply to outpatients with CAP or to inpatients with hospital-acquired pneumonia or ventilator-associated pneumonia. Several ongoing randomized trials probably will clarify steroid use further for pneumonia indications.

Source:
The Cost-effectiveness of Corticosteroids for the treatment of Community-Acquired Pneumonia
Chest. 2018 Nov 15. pii: S0012-3692(18)32727-2. doi: 10.1016/j.chest.2018.11.001.
https://www.ncbi.nlm.nih.gov/pubmed/30448195?dopt=Abstract

Home oxygen therapy for COPD: Does it matter whether the patient is hypoxemic? Evidence vs Reality

Home oxygen therapy for COPD: Does it matter whether the patient is hypoxemic? Evidence vs Reality?

Long-term oxygen therapy (LTOT) is given to improve survival time in people with COPD and severe chronic hypoxemia at rest. The efficacy of oxygen therapy for breathlessness and health-related quality of life (HRQOL) in people with COPD and mild or no hypoxemia who do not meet the criteria for LTOT has not been established. Scientific evidence for its benefits of LTOT dates back to the 1980s when two randomized controlled trials showed prolonged survival in COPD-patients undergoing LTOT for at least 15 hours/day. In contrast, the potential benefits of LTOT in non-COPD-patients has not been well researched and the recommendations for its application are primarily extrapolated from trials on COPD-patients.

Recent Cochrane analysis found that oxygen can relieve breathlessness when given during exercise to mildly hypoxaemic and non-hypoxaemic people with chronic obstructive pulmonary disease who would not otherwise qualify for home oxygen therapy. Findings show that COPD patients without severe hypoxemia undergoing oxygen therapy during exercise training over time do not achieve better exercise capacity or health-related quality of life compared with placebo.

However, LTOT has a beneficial effect on quality of life, dyspnea, and exercise capacity in patients with COPD and exertional hypoxemia.

Source:
Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006429.pub3/full

J Bras Pneumol. 2018 Sep-Oct;44(5):390-397. doi: 10.1590/S1806-37562017000000019.
Impact of adherence to long-term oxygen therapy on patients with COPD and exertional hypoxemia followed for one year.
https://www.ncbi.nlm.nih.gov/pubmed/30517340

Latest in Pulmonary Research

  1. Horn, DM, Schulman, K. Impact of 340B Exposure on Treatment Utilization and Cost for Medicare Patients With Cancer. Health Serv Res. 2026;61 (1):e70092. doi: 10.1111/1475-6773.70092. PubMed PMID:41693003 .
  2. Gäddman Johansson, R, Engwall, K. Redefining Professionalism in Disability Services: Digital Transformation, Boundary Work, and Professional Capital in Frontline Care During the COVID-19 Pandemic. J Appl Res Intellect Disabil. 2026;39 (1):e70196. doi: 10.1111/jar.70196. PubMed PMID:41692995 .
  3. Klicperova-Baker, M, Jelinek, M, Kveton, P. Susceptibility to Disinformation: A Data-Driven Typology Based on COVID-19 Hoaxes and Pro-Russian Propaganda. Int J Psychol. 2026;61 (2):e70186. doi: 10.1002/ijop.70186. PubMed PMID:41692952 .
  4. Okumura, K, Kawanishi, T, Abe, Y, Tanami, H, Sugano, N. Recurrent obturator hernia in a patient with autosomal dominant polycystic kidney disease undergoing peritoneal dialysis: a case report. CEN Case Rep. 2026;15 (2):55. doi: 10.1007/s13730-026-01093-7. PubMed PMID:41692931 .
  5. Jeon, ET, Kim, DH, Park, H, Lee, JK, Heo, EY, Lee, CH et al.. Prolonged expiratory time constant and risk of moderate-to-severe exacerbations in stable COPD. Sci Rep. 2026; :. doi: 10.1038/s41598-026-39987-2. PubMed PMID:41692881 .
  6. Uedono, H, Mori, K, Nakatani, S, Watanabe, K, Furuya, M, Morioka, F et al.. An autopsy-proven case of normotensive scleroderma renal crisis with refractory pleuroperitoneal effusion. CEN Case Rep. 2026;15 (2):52. doi: 10.1007/s13730-025-01043-9. PubMed PMID:41692874 .
  7. Wang, J. Asymmetric division rejuvenates stem cell lineages. Cell Res. 2026; :. doi: 10.1038/s41422-026-01226-8. PubMed PMID:41692871 .
  8. Aleidi, SM, A Hagyousif, Y, Sharaf, BM, Almasri, FA, Al-Iede, M, Al Zayadneh, E et al.. Untargeted metabolomics profiling of childhood asthma: linking metabolic pattern to disease severity. Mol Cell Pediatr. 2026;13 (1):6. doi: 10.1186/s40348-026-00219-2. PubMed PMID:41692866 .
  9. Hsieh, MJ, Wu, CY, Wu, YF, Chen, KA, Gonzalez-Rivas, D, Wu, CF et al.. Early clinical and economic outcomes of uniportal robotic- and video-assisted thoracoscopic surgery for lung anatomic resection: a retrospective study. J Robot Surg. 2026;20 (1):256. doi: 10.1007/s11701-026-03218-7. PubMed PMID:41692862 .
  10. Zhu, H, Li, R, Wen, X, Luo, W, Liu, Q. Convergence of immunometabolism and lung cancer therapy: redefining the tumor-immune interface. Eur J Med Res. 2026; :. doi: 10.1186/s40001-026-04011-w. PubMed PMID:41692828 .
  11. Vega, L, Birchenall-Jiménez, CI, Aponte, A, Durán, D, López, C, Moreno-Matson, MC et al.. Contrasting the gut microbiome in Colombian patients with diarrhea: a comparative metagenomic study in hospitalization and emergency room services. Gut Pathog. 2026; :. doi: 10.1186/s13099-026-00809-5. PubMed PMID:41692795 .
  12. Yu, H, Saffaran, S, Ali, A, Henry, C, Mustfa, N, Thomas, A et al.. In-hospital testing of NIVPredict - an AI tool for early prediction of non-invasive ventilation outcome in acute respiratory failure. Crit Care. 2026; :. doi: 10.1186/s13054-026-05894-1. PubMed PMID:41692794 .
  13. Zhu, Y, Wang, H, Yao, Y, Ding, H, Xu, L, Xu, X et al.. SLC1A5-mediated kynurenine metabolism drives AHR-FANCD2 axis to remodel chromatin and induce T cell exhaustion in lung adenocarcinoma. Cell Commun Signal. 2026; :. doi: 10.1186/s12964-026-02732-3. PubMed PMID:41692781 .
  14. Sitte, HH, Hübner, J, Aust, N, Weisshäupl, V, Ernst, E. Trials and tribulations of responsible people trying to uphold scientific standards. Res Integr Peer Rev. 2026;11 (1):5. doi: 10.1186/s41073-026-00191-5. PubMed PMID:41692741 .
  15. Zhong, W, Wu, S, Zhu, R, Shi, H, Yu, W, Liu, L et al.. Optimal sequencing of brain radiotherapy and immunotherapy for patients with non-small cell lung cancer and driver gene-negative, asymptomatic brain metastases. BMC Cancer. 2026; :. doi: 10.1186/s12885-026-15706-y. PubMed PMID:41692709 .
  16. de Miguel-Díez, J, Castillo-Padrós, M, Figueira-Gonçalves, JM, Torres-Castro, R, Gainza-Miranda, D, Golpe, R et al.. Consensus Document on the Multidisciplinary Management of Advanced-Stage Respiratory Diseases. Arch Bronconeumol. 2026; :. doi: 10.1016/j.arbres.2026.01.014. PubMed PMID:41692675 .
  17. Chen, YT, Cheng, YC, Weng, KC, Lin, MS, Liao, HY, Ho, SY et al.. Non-SARS-CoV-2 respiratory tract infections in pediatric populations during the pandemic. J Microbiol Immunol Infect. 2026; :. doi: 10.1016/j.jmii.2026.01.006. PubMed PMID:41692674 .
  18. Green, N, Vu, P, Xie, J, Schwarzenberg, SJ, Freedman, S, Narkewicz, M et al.. Impact of elexacaftor/tezacaftor/ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function and fat malabsorption: Report of PROMISE pediatric substudy. J Cyst Fibros. 2026; :. doi: 10.1016/j.jcf.2026.02.005. PubMed PMID:41692662 .
  19. Teng, H, Huang, TW. Reply to the comment on "Long-term prognosis of complex versus simple segmentectomy for stage I non-small cell lung cancer". J Formos Med Assoc. 2026; :. doi: 10.1016/j.jfma.2026.02.015. PubMed PMID:41692639 .
  20. Gaertner, J, Hentsch, L, Guerreiro, I, Kannape, OA, Delahaye, M, Bianchi, F et al.. Dyspnoea patterns in patients with advanced diseases: a functional MRI feasibility study protocol. BMJ Open. 2026;16 (2):e107472. doi: 10.1136/bmjopen-2025-107472. PubMed PMID:41692519 .
  21. Yang, J, Chai, H, Zhu, J, Cui, X, Li, W, Su, Q et al.. Anlotinib ameliorates myositis-associated interstitial lung disease (MAILD) via suppression of the NETs-PI3K/Akt-driven epithelial-mesenchymal transition. RMD Open. 2026;12 (1):. doi: 10.1136/rmdopen-2025-006443. PubMed PMID:41692509 .
  22. Tolentino, RH, Patel, D, Yeung, M, Schuenke, MD, Sholl, M, Gugliucci, M et al.. Severe traumatic brain injury: non-military patients' essential need for behavioural healthcare. BMJ Case Rep. 2026;19 (2):. doi: 10.1136/bcr-2025-269121. PubMed PMID:41692484 .
  23. Hayase, N, Kaneda, Y, Fukuno, K, Kanemura, N. Acquired Pure Red Cell Aplasia Following BNT162b2 mRNA COVID-19 Vaccination. Intern Med. 2026;65 (4):569-572. doi: 10.2169/internalmedicine.5233-24. PubMed PMID:41692453 .
  24. Cai, Y, Wang, X, Xu, D, Song, Y, Zhu, L, Peng, W et al.. Gamabufotalin impedes NSCLC progression by inhibiting the mitochondrial factor CHCHD2 and modulating XAF1 expression. Biochem Pharmacol. 2026; :117809. doi: 10.1016/j.bcp.2026.117809. PubMed PMID:41692347 .
  25. Lugogo, NL, Han, JK, Peters, AT, Lee, SE, Kraft, M, Margolis, MK et al.. Tezepelumab's effects on patient-reported symptoms in severe asthma, overall and with history of comorbid CRSwNP. Ann Allergy Asthma Immunol. 2026; :. doi: 10.1016/j.anai.2026.02.002. PubMed PMID:41692339 .
Search PubMed

Search Terms: Asthma, COPD, Lung Cancer, Pneumonia, Pulmonary Fibrosis

Copyright © 2016 Allergy Sleep & Lung Care. All Rights Reserved.
This website does not contain medical advice and the use of this website does not create a physician/patient relationship between you and Allergy Sleep & Lung Care.
Terms of Use | HIPAA Privacy Policy | Sitemap | Privacy Policy

Go to Top